Clinical Trial News and Research

RSS

COTI announces favourable independent pre-IND gap analysis report for novel oncology drug candidate

Critical Outcome Technologies Inc. announced today that it received a favourable Pre-Investigational New Drug (pre-IND) gap analysis report from an independent team that reviewed its novel oncology drug candidate COTI-2. This represents an important milestone as the Company draws closer to a Phase 1 clinical trial.

12 May 2010

Response Genetics, GSK sign non-exclusive license agreement for BRAF mutational analysis technology

Response Genetics, Inc., a company focused on the development and sale of molecular diagnostic tests for cancer, today announced it has signed a non-exclusive license agreement with GlaxoSmithKline ("GSK"). Under the terms of the agreement, GSK gains certain rights to Response Genetics' proprietary PCR analysis technology and diagnostic expertise to assess BRAF gene mutations in human tumor samples. Payments will be made to Response Genetics upon achivement of agreed-to milestones.

12 May 2010

Sanofi-aventis commences multinational Phase IIIb PALLAS trial of Multaq in permanent AF patients

Sanofi-aventis announced today the initiation of a multinational, randomized double-blind Phase IIIb trial, PALLAS, to assess the potential clinical benefit of Multaq(R) (dronedarone) in over 10, 000 patients with permanent atrial fibrillation (AF) to reduce major adverse cardiovascular events. The announcement was made during Heart Rhythm 2010, the Heart Rhythm Society's 31st Annual Scientific Sessions.

12 May 2010

Study confirms Resveratrol's impact on cognitive processes of the brain

The subject of extensive studies across the world, Resveratrol is proving to be a major talking point in the scientific community. And as evidence comes to light of the continuing beneficial effects of this compound, a further study by the University of Northumbria in the UK has confirmed what many scientists already believe to be the case - that Resveratrol could have a significant impact on the cognitive processes of the human brain.

12 May 2010

Adult patients with sickle cell disease may develop cognitive problems: Study

Sickle cell disease may affect brain function in adults who have few or mild complications of the inherited blood disease, according to results of the first study to examine cognitive functioning in adults with sickle cell disease.

12 May 2010

Quest initiates dosing in Phase I clinical trial with SL052 Photodynamic Therapy in prostate cancer patients

Quest PharmaTech Inc., a pharmaceutical company developing and commercializing products for the treatment of cancer, today announced the dosing of the first patient under the Company's recently initiated Phase I clinical trial with SL052 Photodynamic Therapy in prostate cancer patients. The study will evaluate the localization, safety, tolerability and preliminary treatment response of SL052 photodynamic therapy in 18 patients with localized prostate cancer.

12 May 2010

Preliminary data from Achillion Pharmaceuticals' Phase 1b clinical trial of ACH-1625 reported

Achillion Pharmaceuticals, Inc. today reported additional preliminary data from its Phase 1b clinical trial of ACH-1625, which demonstrated that both the third and fourth patient cohorts receiving treatment with ACH-1625 achieved meaningful reductions in HCV RNA after five-day monotherapy, with continued safety and tolerability in patients with hepatitis C.

12 May 2010

EntreMed adds DF/HCC hospitals to Phase 2 study of ENMD-2076 for platinum resistant ovarian cancer

EntreMed, Inc., today announced the addition of Dana Farber/Harvard Cancer Center (DF/HCC) to the Phase 2 multi-center study entitled "A Phase 2 Study of Oral ENMD-2076 Administered to Patients with Platinum Resistant Ovarian Cancer." Ursula Matulonis, M.D., Associate Professor of Medicine, Dana-Farber Cancer Institute and Harvard Medical School, will serve as principal investigator.

11 May 2010

China Pharma first-quarter revenue up 16% to $15.1 million

China Pharma Holdings, Inc., a leading fully-integrated specialty pharmaceuticals company in China, today announced financial results for the first quarter ended March 31, 2010.

11 May 2010

MediciNova announces $15 million senior secured term loan with Oxford Finance

MediciNova, Inc., a biopharmaceutical company that is publicly traded on the Nasdaq Global Market and the Hercules Market of the Osaka Securities Exchange, today announced that it has entered into a $15 million senior secured term loan with Oxford Finance Corporation.

11 May 2010

Medtronic announces new M-Link cellular accessory

Medtronic, Inc. announced today that it now offers the new Medtronic M-Link™ cellular accessory, which provides cardiac device patients with an option to securely send information stored in their implanted devices to their clinics via the CareLink® Network using cellular signals, rather than a telephone landline. This simplified connection to the CareLink® Network enables clinicians to remotely monitor more patients who are implanted with cardiac devices.

11 May 2010

Transition Therapeutics reports increased revenue in third-quarter 2010

Transition Therapeutics Inc., a product-focused biopharmaceutical company developing therapeutics for disease indications with large markets, today announced its financial results for the quarter ended March 31, 2010.

11 May 2010

Intercell reports EUR 4.8m revenue, EUR 14.7m net loss for first-quarter 2010

Today, the biotech-vaccine company Intercell AG announced its financial results for Q1 and presented an update on the Company's development programs.

11 May 2010

Progenics Pharmaceuticals reports net loss of $18.6M in first-quarter 2010

Progenics Pharmaceuticals, Inc. today announced its results of operations for the quarter ended March 31, 2010.

11 May 2010

Poniard Pharmaceuticals reports net loss of $11.9M in first-quarter 2010

Poniard Pharmaceuticals, Inc., a biopharmaceutical company focused on innovative oncology therapies, today reported financial results for the first quarter ended March 31, 2010.

11 May 2010

Sucampo presents phase 3 trial results of lubiprostone in non-cancer pain patients with OBD at DDW 2010

Sucampo Pharmaceuticals, Inc. today announced the presentation of results from a phase 3 clinical trial investigating the use of lubiprostone in non-cancer pain patients with Opioid-induced Bowel Dysfunction (OBD). These results were the subject of an oral presentation at the Digestive Disease Week (DDW) 2010 conference in New Orleans, Louisiana, on May 5, 2010.

11 May 2010

Sucampo reports $0.3M net loss, $14.8M total revenue for first-quarter 2010

Sucampo Pharmaceuticals, Inc. today reported its consolidated financial results for the quarter ended March 31, 2010.

11 May 2010

Can familiar voices heal traumatic brain injuries?

In January 2009, Ryan, a 21-year-old college student from Huntley, Ill., was in a coma after he had been flung from his snowmobile into a tree during an ice storm. He had a traumatic brain injury; the fibers of his brain had been twisted and stretched from the impact.

11 May 2010

Orexigen Therapeutics first-quarter net loss decreases to $14.1 million

Orexigen® Therapeutics, Inc., a biopharmaceutical company focused on the treatment of obesity, today announced financial results for the first quarter of 2010. For the quarter ended March 31, 2010, Orexigen reported a net loss of $14.1 million, or $0.30 per share attributable to common stockholders, as compared to a net loss of $19.3 million, or $0.56 per share attributable to common stockholders, for the first quarter of 2009.

11 May 2010

BIOTRONIK launches TactiCath irrigated RF contact force ablation catheter for treating AF

BIOTRONIK SE & Co. KG, a leading manufacturer of implantable cardiac devices and pioneer of remote monitoring technologies today announced the market release of the TactiCath catheter. The TactiCath catheter, an Endosense company product, is an irrigated RF contact force ablation catheter with features that offer a major advance in ablation therapy for patients with cardiac arrhythmias and particularly Atrial Fibrillation (AF).

11 May 2010

Clinical Trial News and Research

COTI announces favourable independent pre-IND gap analysis report for novel oncology drug candidate

Response Genetics, GSK sign non-exclusive license agreement for BRAF mutational analysis technology

Sanofi-aventis commences multinational Phase IIIb PALLAS trial of Multaq in permanent AF patients

Study confirms Resveratrol's impact on cognitive processes of the brain

Adult patients with sickle cell disease may develop cognitive problems: Study

Quest initiates dosing in Phase I clinical trial with SL052 Photodynamic Therapy in prostate cancer patients

Preliminary data from Achillion Pharmaceuticals' Phase 1b clinical trial of ACH-1625 reported

EntreMed adds DF/HCC hospitals to Phase 2 study of ENMD-2076 for platinum resistant ovarian cancer

China Pharma first-quarter revenue up 16% to $15.1 million

MediciNova announces $15 million senior secured term loan with Oxford Finance

Medtronic announces new M-Link cellular accessory

Transition Therapeutics reports increased revenue in third-quarter 2010

Intercell reports EUR 4.8m revenue, EUR 14.7m net loss for first-quarter 2010

Progenics Pharmaceuticals reports net loss of $18.6M in first-quarter 2010

Poniard Pharmaceuticals reports net loss of $11.9M in first-quarter 2010

Sucampo presents phase 3 trial results of lubiprostone in non-cancer pain patients with OBD at DDW 2010

Sucampo reports $0.3M net loss, $14.8M total revenue for first-quarter 2010

Can familiar voices heal traumatic brain injuries?

Orexigen Therapeutics first-quarter net loss decreases to $14.1 million

BIOTRONIK launches TactiCath irrigated RF contact force ablation catheter for treating AF

Event guide: 15th World Clinical Biomarkers & CDx Europe eBook

Latest eBooks

Editorial Focus eBook - Proteomics (2nd Edition)

Industry Focus eBook - Life Science Microscopy (2nd Edition)

BFEB: Advances in microplate-based assays and analysis

Biologics stability screening toolkit: Three practical workflows for accelerating formulation development

Advancing Neuroscience Research Through Collaboration and Patient-Centered Innovation

The impact of vibration on microscopy

How Omics Technologies Are Transforming Biological Research and Drug Discovery